Navigating Uncertainty in FDA Leadership and Pharma Relations

This chapter examines the upcoming confirmation hearings for a crucial FDA figure and the intense scrutiny they will undergo. It also discusses an important meeting between pharmaceutical executives and the President, focusing on critical issues like drug pricing and agency funding cuts.